Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice

Fundamental & Clinical Pharmacology
Esen GumusluGuner Ulak

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has modulating effects on insulin release. GLP-1 and receptors for GLP-1 are widely expressed throughout the body including the brain. The expression of GLP-1 receptors is very specific to large neurons in hippocampus, neocortex, and cerebellum. GLP-1 receptor stimulation enhances glucose-dependent insulin secretion and lowers blood glucose in type 2 diabetes mellitus. Studies on adipobiology of neurotrophins have focused on nerve growth factor (NGF) as an example of adipose-derived neurotrophins. Compromised trophic factor signaling may underlie neurodegenerative diseases ranging from Alzheimer's disease to diabetic neuropathies. Exenatide, a potent and selective agonist for the GLP-1 receptor, is currently approved for the treatment of type 2 diabetes mellitus. The aim of this study was to assess the effect of chronic exenatide treatment on the hippocampal gene expression levels of GLP-1 receptor and NGF in diabetic mice. The effects of chronic exenatide treatment (0.1 μg/kg, s.c., twice daily for 2 weeks) on GLP-1 receptor and NGF gene expression levels in the hippocampus of streptozotocin/nicotinamide (STZ-NA)-induced diabetic mice were assessed by quantitative rea...Continue Reading

References

May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
Oct 14, 1988·Diabetes Research and Clinical Practice·T MatsuyamaS Tarui
Aug 22, 1997·The Journal of Biological Chemistry·C Montrose-RafizadehJ Eng
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·TracyAnn PerryNigel H Greig
Aug 30, 2002·British Journal of Haematology·Hakan SavliSeppo Pakkala
Aug 7, 2003·Biochemical and Biophysical Research Communications·Victor A GaultFinbarr P M O'Harte
Aug 20, 2003·Nature Medicine·Matthew J DuringColin N Haile
Dec 12, 2003·Experimental Diabesity Research·Gary Pittenger, Aaron Vinik
Oct 27, 2004·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·S GeneriniL Aloe
Nov 6, 2004·Reviews in the Neurosciences·Tara L Spires, Bradley T Hyman
Feb 3, 2007·Digestive Diseases and Sciences·Eldo E FrezzaMaurizio Chiriva-Internati
Mar 14, 2007·Endocrine Reviews·Bernardo L Wajchenberg
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Sep 13, 2008·Molecular and Cellular Endocrinology·Jens Juul HolstCarolyn F Deacon
Sep 22, 2009·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Selda Gezginci-Oktayoglu, Sehnaz Bolkent
Nov 10, 2009·Diabetes Research and Clinical Practice·J E ShawP Z Zimmet
Oct 4, 2011·The Open Medicinal Chemistry Journal·Mohamed LotfyErnest Adeghate
Jul 31, 2013·Journal of Pharmaceutical Sciences·Ting ChenDonald E Mager

❮ Previous
Next ❯

Citations

Nov 5, 2019·Journal of Biochemical and Molecular Toxicology·Mümin A ErdoğanDilek Taşkıran
Oct 7, 2020·Fundamental & Clinical Pharmacology·Dao-Cai WangYong-Mei Xie
Sep 7, 2019·Biochemical Pharmacology·Marcelo Florencio Passos SilvaFernando Maurício Francis Abdalla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.